Mursla Bio presented data at The Liver Meeting suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity

CEO Pierre Arsѐne describes how the test analyses hepatocyte extracellular vesicles, and how he believes this result surpasses the current standards of testing such as ultrasound and alpha-fetoprotein testing.